The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The Anatomy of Medical Research: US and International Comparisons
Abstract
IMPORTANCE: Medical research is a prerequisite of clinical advances, while health service research supports improved delivery, access, and cost. Few previous analyses have compared the United States with other developed countries. OBJECTIVES: To quantify total public and private investment and personnel (economic inputs) and to evaluate resulting patents, publications, drug and device approvals, and value created (economic outputs). EVIDENCE REVIEW: Publicly available data from 1994 to 2012 were compiled showing trends in US and international research funding, productivity, and disease burden by source and industry type. Patents and publications (1981-2011) were evaluated using citation rates and impact factors. FINDINGS: (1) Reduced science investment: Total US funding increased 6% per year (1994-2004), but rate of growth declined to 0.8% per year (2004-2012), reaching $117 billion (4.5%) of total health care expenditures. Private sources increased from 46% (1994) to 58% (2012). Industry reduced early-stage research, favoring medical devices, bioengineered drugs, and late-stage clinical trials, particularly for cancer and rare diseases. National Insitutes of Health allocations correlate imperfectly with disease burden, with cancer and HIV/AIDS receiving disproportionate support. (2) Underfunding of service innovation: Health services research receives $5.0 billion (0.3% of total health care expenditures) or only 1/20th of science funding. Private insurers ranked last (0.04% of revenue) and health systems 19th (0.1% of revenue) among 22 industries in their investment in innovation. An increment of $8 billion to $15 billion yearly would occur if service firms were to reach median research and development funding. (3) Globalization: US government research funding declined from 57% (2004) to 50% (2012) of the global total, as did that of US companies (50% to 41%), with the total US (public plus private) share of global research funding declining from 57% to 44%. Asia, particularly China, tripled investment from $2.6 billion (2004) to $9.7 billion (2012) preferentially for education and personnel. The US share of life science patents declined from 57% (1981) to 51% (2011), as did those considered most valuable, from 73% (1981) to 59% (2011). CONCLUSIONS AND RELEVANCE: New investment is required if the clinical value of past scientific discoveries and opportunities to improve care are to be fully realized. Sources could include repatriation of foreign capital, new innovation bonds, administrative savings, patent pools, and public-private risk sharing collaborations. Given international trends, the United States will relinquish its historical international lead in the next decade unless such measures are undertaken.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given these demands, many RCTs are conducted with substantial industry funding, and the pharmaceutical industry remains one of the main sponsors of health research (Flacco et al. 2015; Moses et al. 2015; Holman and Elliott 2018).”
From Sponsorship bias in randomised controlled trials on postoperative pain after third molar extraction: A meta-research study (2026) · cites this paper as Moses et al. 2015
In the citing paper
“Also, many research projects in the USA are funded by private initiatives, unlike most other countries 29 , 30 , 31 .”
From Global mapping of randomized controlled trials in dentistry (2024) · cites this paper as [31]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [26]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [26]
Citations
Cites
The lever of riches: technological creativity and economic progress
(1990) · Choice Reviews Online · doi:10.5860/choice.28-1056 · Cited by 1,900
The Handbook of Organizational Economics
Gibbons, R. S., & Roberts, J. (2012) · Princeton University Press eBooks · doi:10.1515/9781400845354 · Cited by 720
Introduction of surgical safety checklists in Ontario, Canada
Urbach, D. R., Govindarajan, A., Saskin, R., Wilton, A. S., & Baxter, N. N. (2014) · New England Journal of Medicine · doi:10.1056/nejmsa1308261 · Cited by 627
The Wealth of Knowledge: Intellectual Capital and the Twenty-first Century Organization
Stewart, T. A. (2001) · Medical Entomology and Zoology · Cited by 526
The Relation between Funding by the National Institutes of Health and the Burden of Disease
Gross, C. P., Anderson, G. F., & Powe, N. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402406 · Cited by 509
Financial Anatomy of Biomedical Research
Moses, H., Dorsey, E. R., Matheson, D. H. M., & Thier, S. O. (2005) · JAMA · doi:10.1001/jama.294.11.1333 · Cited by 448
Self-citationFunding of US Biomedical Research, 2003-2008
Dorsey, E. R. (2010) · JAMA · doi:10.1001/jama.2009.1987 · Cited by 337
Self-citationThe Anatomy of Health Care in the United States
Moses, H., Matheson, D. H. M., Dorsey, E. R., George, B. P., Sadoff, D., & Yoshimura, S. (2013) · JAMA · doi:10.1001/jama.2013.281425 · Cited by 328
Self-citationCryer, L., Shannon, S. B., Amsterdam, M. V., & Leff, B. A. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1132 · Cited by 282
NIH Disease Funding Levels and Burden of Disease
Gillum, L. A., Gouveia, C., Dorsey, E. R., Pletcher, M., Mathers, C. D., McCulloch, C. E., & Johnston, S. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016837 · Cited by 248
Self-citationHealth Care Reform and Cost Control
Orszag, P. R., & Emanuel, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006571 · Cited by 248
Relationship Between Occurrence of Surgical Complications and Hospital Finances
Eappen, S., Lane, B. H., Rosenberg, B. L., Lipsitz, S. R., Sadoff, D., Matheson, D., Berry, W. R., Lester, M., & Gawande, A. A. (2013) · JAMA · doi:10.1001/jama.2013.2773 · Cited by 221
Self-citationArriaga, A. F., Gawande, A. A., Raemer, D. B., Jones, D. B., Smink, D. S., Weinstock, P. H., Dwyer, K., Lipsitz, S. R., Peyre, S. E., Pawlowski, J., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0000000000000342 · Cited by 146
Asia's Ascent — Global Trends in Biomedical R&D Expenditures
Chakma, J., Sun, G. H., Steinberg, J. D., Sammut, S. M., & Jagsi, R. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1311068 · Cited by 130
Pearl, R. M. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1005 · Cited by 120
Clinical Research in the United States at a Crossroads
Crowley, W. F., Sherwood, L. M., Salber, P. R., Scheinberg, D. A., Slavkin, H., Tilson, H. H., Reece, E. A., Catanese, V. M., Johnson, S. B., Dobs, A. S., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1120 · Cited by 116
Life out of sequence: a data-driven history of bioinformatics
(2014) · Choice Reviews Online · doi:10.5860/choice.51-5587 · Cited by 76
Bayh-Dole Reform and the Progress of Biomedicine
Rai, A. K., & Eisenberg, R. S. (2003) · American Scientist · doi:10.1511/2003.11.842 · Cited by 73
Diminishing Returns?: The Costs and Benefits of Improving Health
Murphy, K., & Topel, R. (2003) · Perspectives in biology and medicine · doi:10.1353/pbm.2003.0077 · Cited by 70
Taming the beloved beast: how medical technology costs are destroying our health care system
Callahan, D. 1.-2. (2010) · Choice Reviews Online · doi:10.5860/choice.47-5928 · Cited by 50
Biomedical Research and Health Advances
Moses, H., & Martin, J. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1007634 · Cited by 47
Self-citationGrowing time lag threatens Nobels
Fortunato, S. (2014) · Nature · doi:10.1038/508186a · Cited by 42
A Better Route to Tech Standards
Lerner, J., & Tirole, J. (2014) · Science · doi:10.1126/science.1246439 · Cited by 32
Pronovost, P. J., & Wachter, R. M. (2013) · American Journal of Medical Quality · doi:10.1177/1062860613495554 · Cited by 27
The Future of Biomedical Research
Emanuel, E. (2013) · JAMA · doi:10.1001/jama.2013.2096 · Cited by 26
Hoffman, A., & Emanuel, E. J. (2013) · JAMA · doi:10.1001/jama.2012.214571 · Cited by 22
NIH inventions translate into drugs and biologics with high public health impact
Chatterjee, S. K., & Rohrbaugh, M. L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2785 · Cited by 21
Regulators adopt more orphan drugs
Reardon, S. (2014) · Nature · doi:10.1038/508016a · Cited by 20
Ties that Bind: Strategic Stability in the U.S.–China Relationship
Fingar, T., & Fan, J. (2013) · The Washington Quarterly · doi:10.1080/0163660x.2013.861718 · Cited by 15
Brief History of NIH Funding: Fact Sheet
Johnson, J. A. (2013) · University of North Texas Digital Library (University of North Texas) · Cited by 12
Technological Innovation and Organizations
Azoulay, P., & Lerner, J. (2012) · Princeton University Press eBooks · doi:10.2307/j.ctt1r2ggg.18 · Cited by 11
A Health Care Encounter of the 21st Century
Cortese, D. A. (2013) · JAMA · doi:10.1001/jama.2013.281856 · Cited by 9
Drug makers and NIH team up to find and validate targets
Mullard, A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4293 · Cited by 8
Goodwin, I. (2000) · Physics Today · doi:10.1063/1.883075 · Cited by 5
Flagged first, then by citations
Cited by
Sorted by citations
An introduction to implementation science for the non-specialist
Bauer, M. S., Damschroder, L. J., Hagedorn, H., Smith, J. L., & Kilbourne, A. M. (2015) · BMC Psychology · doi:10.1186/s40359-015-0089-9 · Cited by 2,168
Murray, C. J. L., Barber, R. M., Foreman, K. J., Özgören, A. A., Abd-Allah, F., Abera, S. F., Aboyans, V., Abraham, J. P., Abubakar, I., Abu-Raddad, L. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61340-x · Cited by 1,966
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Dorsey, E. R., & Topol, E. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601705 · Cited by 1,211
Self-citationThe High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
Metadata
- Authors
- Moses, H., Matheson, D. H. M., Cairns-Smith, S., George, B. P., Palisch, C., & Dorsey, E. R.
- Affiliations
- Johns Hopkins University (US)
- Boston Consulting Group (United States) (US)
- Boston Consulting Group, Boston, Massachusetts
- University of Rochester Medicine (US)
- Stanford Medicine (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-01-13
- Volume
- 313
- Issue
- 2
- Pages
- 174
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2099877908
- Cited by
- 446
- References
- 34
- Citations by year
- 2026: 21 · 2025: 37 · 2024: 24 · 2023: 32 · 2022: 30 · 2021: 40 · 2020: 37 · 2019: 36 · 2018: 47 · 2017: 46 · 2016: 56 · 2015: 39
- FWCI
- 67.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Business, Management and Accounting › Management of Technology and Innovation › Research, Science, and Academia
- Keywords
- health research funding, research investment, health services research, research productivity, National Institutes of Health, globalization of science, health care expenditure, rare diseases, cancer research, HIV/AIDS research, citation counts, impact factor, health system innovation
- MeSH terms
- Clinical Trials as Topic, Efficiency, Health Expenditures, Health Services Research, Industry, National Institutes of Health (U.S.), Patents as Topic, Publishing, Research Support as Topic, United States, Private Sector, Drug Approval, Device Approval, Biomedical Research, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
